Quintrio
Home

Stock overview

Evotec SE American Depositary Shares

EVO

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Last trade $1.45
Day change -$0.11 (-7.05%)
Day range $1.45 – $1.56
Volume 59,025
Market cap $554M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for EVO.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for EVO.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

BIO-Europe 2026 to Convene Global Biopharma Decision-Makers in Cologne

BIO-Europe 2026 will host over 6,000 senior leaders from the global biopharma industry in Cologne, Germany, from November 9-11, 2026. The 32nd annual edition expands beyond partnering to become Europe's largest biopharma strategy forum, featuring seven integrated tracks covering regulatory, clinical, and manufacturing strategy, with focus on partnerships, innovation, and addressing industry challenges.

GlobeNewswire Inc.

Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider

The global drug repurposing market is projected to grow from USD 34.79 billion in 2025 to USD 50.91 billion by 2035 at a CAGR of 3.93%. North America leads with 39% market share, while Asia-Pacific shows the fastest growth at 5.02% CAGR. Small molecules dominate at 67% market share, with oncology and neurology as primary therapeutic areas. AI and machine learning are accelerating drug discovery, though intellectual property rights remain a key barrier.

GlobeNewswire Inc.

State of the Life Sciences Industry to Be Reviewed in BCC Research's 2026 Second Quarter Outlook, Spotlighting AI-Driven Discovery, Precision Oncology, and Connected Health Adoption

BCC Research's mid-year assessment highlights AI-driven discovery, precision oncology, and connected health as major growth themes in the life sciences sector. Key opportunities include smart inhalers with AI integration, genomic profiling platforms, cardiovascular drug innovations, and in vitro toxicity testing. The sector benefits from aging populations, regulatory support for non-animal testing, and emerging market expansion, though risks include patent expirations and reimbursement variability.

Benzinga

Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal

Gilead Sciences announced a $3.15 billion acquisition of Tubulis GmbH to strengthen its oncology pipeline, adding the promising antibody-drug conjugate TUB-040 for ovarian cancer treatment. The deal includes up to $1.85 billion in contingent milestone payments. This acquisition follows Gilead's March purchase of Ouro Medicines for $1.675 billion, highlighting the company's broader pipeline expansion strategy.

GlobeNewswire Inc.

Evotec Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Johnson Fistel, PLLP is investigating whether Evotec SE complied with federal securities laws following the company's announcement of its 'Horizon' restructuring initiative on March 10, 2026. The investigation focuses on potential investor losses related to Evotec's financial guidance projecting €700-780 million in revenue and €0-40 million in adjusted EBITDA for fiscal year 2026, along with €100 million in restructuring charges expected over 2026-2028.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Jan 11, 2019$0.0722Jan 22, 2019recurring
Dec 12, 2018$0.0451Dec 20, 2018recurring
Nov 8, 2018$0.0451Nov 19, 2018recurring
Oct 10, 2018$0.0451Oct 18, 2018recurring
Sep 13, 2018$0.0451Sep 21, 2018recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.